SGLT2 inhibitors on BlueMedicare Premier Rx (S5795-002)
Jardiance, Farxiga and the other SGLT2 inhibitors, for diabetes, heart failure and kidney disease, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Arkansas
- Premium
- $181.20/month
- Deductible
- None
3 of 6 SGLT2 inhibitors are covered on this plan. None require prior authorization.
3 aren't on the formulary, including Invokana and Steglatro.
- $40.76Tier 3
- $36.32Tier 3
- $0.00Tier 1
Not on the formulary
Invokana, Steglatro, Inpefa
Patient cost for a 30-day supply at a preferred retail pharmacy. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.